S&P 500   3,006.89 (+0.58%)
DOW   27,085.10 (+0.31%)
QQQ   194.40 (+0.70%)
AAPL   235.68 (+0.56%)
FB   190.51 (+0.51%)
MSFT   140.89 (+0.34%)
GOOGL   1,257.93 (+1.20%)
AMZN   1,793.91 (+0.93%)
CGC   20.17 (+2.23%)
NVDA   196.32 (+1.09%)
MU   45.89 (+1.62%)
BABA   177.24 (+0.07%)
GE   8.97 (+0.79%)
TSLA   262.35 (+1.00%)
AMD   31.18 (+1.20%)
T   37.77 (-0.05%)
F   9.09 (+0.22%)
ACB   3.75 (+3.88%)
PRI   124.59 (+0.58%)
NFLX   301.67 (+5.38%)
BAC   30.48 (+0.99%)
GILD   65.52 (+0.26%)
DIS   131.58 (+0.55%)
S&P 500   3,006.89 (+0.58%)
DOW   27,085.10 (+0.31%)
QQQ   194.40 (+0.70%)
AAPL   235.68 (+0.56%)
FB   190.51 (+0.51%)
MSFT   140.89 (+0.34%)
GOOGL   1,257.93 (+1.20%)
AMZN   1,793.91 (+0.93%)
CGC   20.17 (+2.23%)
NVDA   196.32 (+1.09%)
MU   45.89 (+1.62%)
BABA   177.24 (+0.07%)
GE   8.97 (+0.79%)
TSLA   262.35 (+1.00%)
AMD   31.18 (+1.20%)
T   37.77 (-0.05%)
F   9.09 (+0.22%)
ACB   3.75 (+3.88%)
PRI   124.59 (+0.58%)
NFLX   301.67 (+5.38%)
BAC   30.48 (+0.99%)
GILD   65.52 (+0.26%)
DIS   131.58 (+0.55%)
Log in

Leap Therapeutics Stock Price, News & Analysis (NASDAQ:LPTX)

$1.18
-0.01 (-0.84 %)
(As of 10/17/2019 09:54 AM ET)
Today's Range
$1.18
Now: $1.18
$1.18
50-Day Range
$1.14
MA: $1.43
$1.82
52-Week Range
$1.09
Now: $1.18
$6.74
Volume200 shs
Average Volume235,492 shs
Market Capitalization$28.37 million
P/E RatioN/A
Dividend YieldN/A
Beta2.47
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LPTX
CUSIPN/A
Phone617-714-0360

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.62 per share

Profitability

Net Income$-23,140,000.00

Miscellaneous

Employees23
Market Cap$28.37 million
Next Earnings Date11/8/2019 (Estimated)
OptionableNot Optionable

Receive LPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.


Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions

What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics Inc (NASDAQ:LPTX) released its earnings results on Friday, August, 9th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.08. View Leap Therapeutics' Earnings History.

When is Leap Therapeutics' next earnings date?

Leap Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for Leap Therapeutics.

What price target have analysts set for LPTX?

2 equities research analysts have issued 12-month price targets for Leap Therapeutics' shares. Their forecasts range from $5.00 to $13.00. On average, they expect Leap Therapeutics' stock price to reach $9.00 in the next year. This suggests a possible upside of 662.7% from the stock's current price. View Analyst Price Targets for Leap Therapeutics.

What is the consensus analysts' recommendation for Leap Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Leap Therapeutics.

Has Leap Therapeutics been receiving favorable news coverage?

News coverage about LPTX stock has been trending very negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Leap Therapeutics earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Leap Therapeutics.

Are investors shorting Leap Therapeutics?

Leap Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totalling 1,850,000 shares, an increase of 6.3% from the August 30th total of 1,740,000 shares. Based on an average daily trading volume, of 333,100 shares, the short-interest ratio is presently 5.6 days. Approximately 13.0% of the shares of the stock are sold short. View Leap Therapeutics' Current Options Chain.

Who are some of Leap Therapeutics' key competitors?

What other stocks do shareholders of Leap Therapeutics own?

Who are Leap Therapeutics' key executives?

Leap Therapeutics' management team includes the folowing people:
  • Dr. Christopher K. Mirabelli Ph.D., CEO, Pres & Chairman (Age 65)
  • Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec. (Age 50)
  • Mr. Augustine J. Lawlor, Chief Operating Officer (Age 63)

How do I buy shares of Leap Therapeutics?

Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $1.18.

How big of a company is Leap Therapeutics?

Leap Therapeutics has a market capitalization of $28.37 million. The company earns $-23,140,000.00 in net income (profit) each year or ($2.51) on an earnings per share basis. Leap Therapeutics employs 23 workers across the globe.View Additional Information About Leap Therapeutics.

What is Leap Therapeutics' official website?

The official website for Leap Therapeutics is http://www.leaptx.com/.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360.


MarketBeat Community Rating for Leap Therapeutics (NASDAQ LPTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  194 (Vote Outperform)
Underperform Votes:  167 (Vote Underperform)
Total Votes:  361
MarketBeat's community ratings are surveys of what our community members think about Leap Therapeutics and other stocks. Vote "Outperform" if you believe LPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel